Kolltan Pharmaceuticals Inc. Acquires Xetrios Therapeutics And Exclusive Rights To Salk Institute for Biological Studies Patents Related To The TAM Receptor Tyrosine Kinase Family

NEW HAVEN, Conn.--(BUSINESS WIRE)--Kolltan Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs), today announced the acquisition of privately held Xetrios Therapeutics, Inc., a company founded in 2009 by Greg Lemke, Ph.D., of the Salk Institute for Biological Studies in San Diego, California, Carla Rothlin, Ph.D., of Yale University, and biotech entrepreneur Lawrence C. Fritz, Ph.D. Through this acquisition, Kolltan has secured exclusive intellectual property (IP) rights focused on human therapeutics targeting the TAM RTK family.

Help employers find you! Check out all the jobs and post your resume.